Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse ratings for Ligand Pharmaceuticals (NASDAQ:LGND) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3.97% to $133.71. Ligand's recent financial performance shows strong revenue growth but challenges in profitability and asset utilization.
October 21, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals has received a mix of bullish and somewhat bullish ratings from analysts, with an increased average price target of $133.71. The company shows strong revenue growth but faces challenges in profitability and asset utilization.
The increase in the average price target and the majority of bullish ratings suggest a positive short-term outlook for Ligand Pharmaceuticals. However, the company's financial challenges in profitability and asset utilization may temper the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100